Title
Category
Credits
Event date
Cost
  • Alzheimer Disease
  • Antipsychotics
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • Parkinson Disease
  • Psychotic Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Antipsychotics can be used in the short-term to manage dementia-related psychosis, but serious adverse effects can outweigh benefits. Novel antipsychotics or other agents may offer superior efficacy and safety. Explore the evidence in this CME activity.
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
  • Primary Care
  • Patient/Physician Communication
  • Neuroimaging
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
  • Primary Care
  • Neuroimaging
  • Alzheimer Disease
  • Dementia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Early-stage diagnosis of Alzheimer disease leads to prompt treatment initiation and better patient QoL. Learn about new guidelines and technology advances and what’s on the horizon from authorities in the field.
  • Patient/Physician Communication
  • Neurology
  • Neuroimaging
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Functional Impairment
  • Diagnostic Tools
  • Education
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Anderson and Malone cover the types of dementia and their indicators, ways to approach care for mild cognitive impairment (MCI) and mild dementia, and treatment options available or in the pipeline for disease intervention. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
  • Patient/Physician Communication
  • Neurology
  • Neuroimaging
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Functional Impairment
  • Diagnostic Tools
  • Education
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Anderson and Malone discuss the burden of, signs and symptoms of, diagnostic tools and criteria for mild cognitive impairment (MCI) and mild/early dementia and the benefits of early diagnosis. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
  • Alzheimer Disease
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Great strides in research on Alzheimer disease diagnostic biomarkers and treatment targets have taken place over the past 2 decades. Listen as Dr Goldfarb highlights exciting developments.
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Diagnostic Tools
  • Patient/Physician Communication
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this webcast about early-stage Alzheimer disease, Drs Burke and Apostolova highlight important conversations to have with patients and their care partners on topics such as diet, exercise, driving, and plans for the later stage of illness.
  • Alzheimer Disease
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
How do investigational drugs for Alzheimer disease differ from those currently prescribed to patients? Dr Burke shares her insights.
  • Alzheimer Disease
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Experts offer an overview of best practices for managing early-stage Alzheimer disease as well as a look at the future.

Pages